The rapidly expanding and highly specialised pharmaceutical CDMO (Contract Development and Manufacturing Organisation) in India, OneSource Specialty Pharma, has acquired a stake by 360 ONE Asset, one of the country’s asset management companies.
At a critical juncture in OneSource’s development, 360 ONE Asset is purchasing a stake from an existing investor as the business moves closer to its goal of becoming a major force in the fields of biologics, drug-device combinations, complex injectables, and soft gelatine capsules.
Go deeper with GlobalData
OneSource has established solid ties with well-known pharmaceutical and biotech companies worldwide and is well-positioned to benefit from the growing demand for these specialised solutions.
Its leadership in the industry is further reinforced by the fact that it is one of the few Indian businesses with the know-how to create and produce sophisticated goods like GLP-1 medications and innovative biologics.
OneSource is prepared for substantial expansion with a workforce of more than 1,200 workers, including more than 100 scientists and techno-commercial specialists, and five highly automated manufacturing facilities, including four US FDA-approved locations with flawless compliance records.
Tarun Sharma, Fund Manager (Healthcare and Consumer) at 360 ONE Asset stated: “We are delighted to back OneSource, and its stellar team that has built a wide portfolio of capabilities. The company’s leadership in large molecules, complex injectables, and drug-device combinations positions it perfectly for the next phase of growth. We look forward to collaborating with OneSource as they continue their journey of innovation and global expansion.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNeeraj Sharma, CEO of OneSource Specialty Pharma added: “OneSource has established itself as a trusted development and manufacturing partner for top pharmaceutical companies worldwide. Our expertise in niche and complex dosage forms, along with our track record of superior compliance, allows us to provide an integrated, one-stop solution to our global clients. We are glad to welcome 360 ONE Asset as an investor who aligns with our mission to scale further.”
360 ONE Asset, formerly IIFL Asset Management, has a $10bn AUM and a $3bn AUM Venture Capital and Private Equity platform. With expertise in technology, financial services, healthcare, and consumer industries, it offers unique investment opportunities in India.
